CY1112374T1 - Επιλεκτικα του υποτυπου νικοτινικου υποδοχεα της ακετυλχολινης αμιδια διαζαδικυκλοαλκανιων - Google Patents
Επιλεκτικα του υποτυπου νικοτινικου υποδοχεα της ακετυλχολινης αμιδια διαζαδικυκλοαλκανιωνInfo
- Publication number
- CY1112374T1 CY1112374T1 CY20111100706T CY111100706T CY1112374T1 CY 1112374 T1 CY1112374 T1 CY 1112374T1 CY 20111100706 T CY20111100706 T CY 20111100706T CY 111100706 T CY111100706 T CY 111100706T CY 1112374 T1 CY1112374 T1 CY 1112374T1
- Authority
- CY
- Cyprus
- Prior art keywords
- compounds
- effects
- nicotinic
- significant
- amidia
- Prior art date
Links
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 title 1
- 229960004373 acetylcholine Drugs 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 6
- 230000000694 effects Effects 0.000 abstract 4
- -1 amide compounds Chemical class 0.000 abstract 2
- 210000003169 central nervous system Anatomy 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 108010009685 Cholinergic Receptors Proteins 0.000 abstract 1
- 102000019315 Nicotinic acetylcholine receptors Human genes 0.000 abstract 1
- 108050006807 Nicotinic acetylcholine receptors Proteins 0.000 abstract 1
- 102000034337 acetylcholine receptors Human genes 0.000 abstract 1
- 230000002411 adverse Effects 0.000 abstract 1
- 230000036772 blood pressure Effects 0.000 abstract 1
- 210000004556 brain Anatomy 0.000 abstract 1
- 208000015114 central nervous system disease Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 210000001035 gastrointestinal tract Anatomy 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000001537 neural effect Effects 0.000 abstract 1
- 230000000324 neuroprotective effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 210000002027 skeletal muscle Anatomy 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US85607906P | 2006-11-02 | 2006-11-02 | |
| EP07863786A EP2094703B1 (en) | 2006-11-02 | 2007-11-01 | Nicotinic acetylcholine receptorsub-type selective amides of diazabicycloalkanes |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1112374T1 true CY1112374T1 (el) | 2015-12-09 |
Family
ID=39233054
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20111100706T CY1112374T1 (el) | 2006-11-02 | 2011-07-20 | Επιλεκτικα του υποτυπου νικοτινικου υποδοχεα της ακετυλχολινης αμιδια διαζαδικυκλοαλκανιων |
Country Status (32)
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI454262B (zh) * | 2006-11-02 | 2014-10-01 | Targacept Inc | 菸鹼乙醯膽鹼受體亞型選擇性之二氮雜雙環烷類醯胺 |
| CA2716863A1 (en) * | 2008-03-05 | 2009-09-11 | Targacept, Inc. | Sub-type selective amides of diazabicycloalkanes |
| WO2009113950A1 (en) * | 2008-03-10 | 2009-09-17 | Astrazeneca Ab | Therapeutic combinations of (a) an antipsychotic and (b) an alpha-4/beta-2 (a4b2)-neuronal nicotinic receptor agonist |
| WO2009147188A1 (en) | 2008-06-05 | 2009-12-10 | Glaxo Group Limited | Benzpyrazol derivatives as inhibitors of pi3 kinases |
| ES2383246T3 (es) | 2008-06-05 | 2012-06-19 | Glaxo Group Limited | 4-amino-indazoles |
| JP5502076B2 (ja) | 2008-06-05 | 2014-05-28 | グラクソ グループ リミテッド | 新規化合物 |
| EP2344496A1 (en) * | 2008-09-05 | 2011-07-20 | Targacept Inc. | Amides of diazabicyclooctanes and uses thereof |
| WO2010028011A1 (en) * | 2008-09-05 | 2010-03-11 | Targacept, Inc. | Amides of diazabicyclononanes and uses thereof |
| WO2010080757A2 (en) | 2009-01-07 | 2010-07-15 | Astrazeneca Ab | Combinations with an alpha-4beta-2 nicotinic agonist |
| JP5656880B2 (ja) | 2009-03-09 | 2015-01-21 | グラクソ グループ リミテッドＧｌａｘｏ Ｇｒｏｕｐ Ｌｉｍｉｔｅｄ | Ｐｉ３キナーゼの阻害剤としての４−オキサジアゾール−２−イル−インダゾール |
| MY160454A (en) | 2009-04-30 | 2017-03-15 | Glaxo Group Ltd | Oxazole substituted indazoles as pi3-kinase inhibitors |
| RU2417082C2 (ru) * | 2009-07-14 | 2011-04-27 | Учреждение Российской Академии Наук Институт Физиологически Активных Веществ Ран (Ифав Ран) | Средство для восстановления утраченной памяти в норме и патологии у пациентов всех возрастных групп на основе n, n'-замещенных 3, 7-диазабицикло[3.3.1]нонанов, фармацевтическая композиция на его основе и способ ее применения |
| HRP20161461T1 (hr) | 2009-11-18 | 2017-01-27 | Suven Life Sciences Limited | Biciklički spojevi kao ligandi alfa4beta2 nikotinskih acetilakolinskih receptora |
| EA023293B1 (ru) | 2009-12-29 | 2016-05-31 | Сувен Лайф Сайенсиз Лимитед | ЛИГАНДЫ НЕЙРОНАЛЬНОГО НИКОТИНОВОГО АЦЕТИЛХОЛИНОВОГО РЕЦЕПТОРА αβ |
| GB201018124D0 (en) | 2010-10-27 | 2010-12-08 | Glaxo Group Ltd | Polymorphs and salts |
| AR095079A1 (es) | 2013-03-12 | 2015-09-16 | Hoffmann La Roche | Derivados de octahidro-pirrolo[3,4-c]-pirrol y piridina-fenilo |
| AU2014356583B2 (en) | 2013-11-26 | 2019-02-28 | F. Hoffmann-La Roche Ag | New octahydro-cyclobuta (1,2-c;3,4-c')dipyrrol-2-yl |
| AU2015238537B2 (en) | 2014-03-26 | 2019-08-01 | F. Hoffmann-La Roche Ag | Bicyclic compounds as autotaxin (ATX) and lysophosphatidic acid (LPA) production inhibitors |
| PT3848028T (pt) | 2014-10-20 | 2024-09-20 | Oyster Point Pharma Inc | Métodos de tratamento de estados oculares |
| UA123362C2 (uk) | 2015-09-04 | 2021-03-24 | Ф. Хоффманн-Ля Рош Аг | Феноксиметильні похідні |
| CR20180057A (es) | 2015-09-24 | 2018-04-02 | Hoffmann La Roche | Nuevos compuestos biciclicos como inhibidores duales de atx/ca. |
| CR20180072A (es) | 2015-09-24 | 2018-02-26 | Hoffmann La Roche | Nuevos compuestos biciclicos como inhibidores de atx |
| AU2016328535A1 (en) | 2015-09-24 | 2017-11-09 | F. Hoffmann-La Roche Ag | Bicyclic compounds as ATX inhibitors |
| KR20180053408A (ko) | 2015-09-24 | 2018-05-21 | 에프. 호프만-라 로슈 아게 | 이중 오토탁신(atx)/탄산 무수화효소(ca) 억제제로서의 신규한 이환형 화합물 |
| DK3439661T3 (da) | 2016-04-07 | 2021-10-18 | Oyster Point Pharma Inc | Fremgangsmåder til behandling af øjenlidelser |
| SG11201908560SA (en) | 2017-03-16 | 2019-10-30 | Hoffmann La Roche | Heterocyclic compounds useful as dual atx/ca inhibitors |
| CN110382484B (zh) | 2017-03-16 | 2022-12-06 | 豪夫迈·罗氏有限公司 | 新的作为atx抑制剂的二环化合物 |
| DK3448859T3 (da) | 2017-03-20 | 2019-09-23 | Forma Therapeutics Inc | Pyrrolopyrrolsammensætninger som pyruvatkinase- (pkr) aktivatorer |
| WO2020061378A1 (en) | 2018-09-19 | 2020-03-26 | Forma Therapeutics, Inc. | Treating sickle cell disease with a pyruvate kinase r activating compound |
| JP7450610B2 (ja) | 2018-09-19 | 2024-03-15 | ノヴォ・ノルディスク・ヘルス・ケア・アーゲー | ピルビン酸キナーゼｒの活性化 |
| MX2022003254A (es) | 2019-09-19 | 2022-04-18 | Forma Therapeutics Inc | Composiciones activadoras de piruvato cinasa r (pkr). |
| US12128035B2 (en) | 2021-03-19 | 2024-10-29 | Novo Nordisk Health Care Ag | Activating pyruvate kinase R |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4922901A (en) | 1988-09-08 | 1990-05-08 | R. J. Reynolds Tobacco Company | Drug delivery articles utilizing electrical energy |
| IL107184A (en) | 1992-10-09 | 1997-08-14 | Abbott Lab | Heterocyclic ether compounds that enhance cognitive function |
| US5852041A (en) | 1993-04-07 | 1998-12-22 | Sibia Neurosciences, Inc. | Substituted pyridines useful as modulators of acethylcholine receptors |
| US5493026A (en) | 1993-10-25 | 1996-02-20 | Organix, Inc. | Substituted 2-carboxyalkyl-3-(fluorophenyl)-8-(3-halopropen-2-yl) nortropanes and their use as imaging for agents for neurodegenerative disorders |
| US5468858A (en) * | 1993-10-28 | 1995-11-21 | The Board Of Regents Of Oklahoma State University Physical Sciences | N-alkyl and n-acyl derivatives of 3,7-diazabicyclo-[3.3.1]nonanes and selected salts thereof as multi-class antiarrhythmic agents |
| DE69416869T2 (de) * | 1993-12-29 | 1999-07-01 | Pfizer Inc., New York, N.Y. | Diazabicyclische neurokinin antagonisten |
| US5457121A (en) | 1994-09-02 | 1995-10-10 | Eli Lilly And Company | Cis-hexahydro-5-(1,2,3,4-tetrahydro-2-naphthalenyl)pyrrolo<3,4-c>pyrroles as inhibitors of serotonin reuptake |
| US5597919A (en) | 1995-01-06 | 1997-01-28 | Dull; Gary M. | Pyrimidinyl or Pyridinyl alkenyl amine compounds |
| US5604231A (en) * | 1995-01-06 | 1997-02-18 | Smith; Carr J. | Pharmaceutical compositions for prevention and treatment of ulcerative colitis |
| US5585388A (en) | 1995-04-07 | 1996-12-17 | Sibia Neurosciences, Inc. | Substituted pyridines useful as modulators of acetylcholine receptors |
| US5583140A (en) | 1995-05-17 | 1996-12-10 | Bencherif; Merouane | Pharmaceutical compositions for the treatment of central nervous system disorders |
| IL118279A (en) | 1995-06-07 | 2006-10-05 | Abbott Lab | Compounds 3 - Pyridyloxy (or Thio) Alkyl Heterocyclic Pharmaceutical Compositions Containing Them and Their Uses for Preparing Drugs to Control Synaptic Chemical Transmission |
| US5616716A (en) * | 1996-01-06 | 1997-04-01 | Dull; Gary M. | (3-(5-ethoxypyridin)yl)-alkenyl 1 amine compounds |
| SE9600683D0 (sv) * | 1996-02-23 | 1996-02-23 | Astra Ab | Azabicyclic esters of carbamic acids useful in therapy |
| US5663356A (en) | 1996-04-23 | 1997-09-02 | Ruecroft; Graham | Method for preparation of aryl substituted alefinic secondary amino compounds |
| US5726189A (en) * | 1996-05-03 | 1998-03-10 | The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Method for imaging nicotinic acetylcholinergic receptors in the brain using radiolabeled pyridyl-7-azabicyclo 2.2.1!heptanes |
| US5952339A (en) | 1998-04-02 | 1999-09-14 | Bencherif; Merouane | Pharmaceutical compositions and methods of using nicotinic antagonists for treating a condition or disorder characterized by alteration in normal neurotransmitter release |
| EP1274710B1 (en) * | 1999-12-14 | 2005-02-23 | NeuroSearch A/S | Novel heteroaryl-diazabicycloalkanes |
| US6809105B2 (en) * | 2000-04-27 | 2004-10-26 | Abbott Laboratories | Diazabicyclic central nervous system active agents |
| MXPA03008109A (es) | 2001-03-07 | 2003-12-12 | Pfizer Prod Inc | Moduladores de la actividad de receptores de quimiocinas. |
| JP2004532899A (ja) * | 2001-07-06 | 2004-10-28 | ニューロサーチ、アクティーゼルスカブ | 新規化合物、その製造方法及びその使用方法 |
| SE0202430D0 (sv) * | 2002-08-14 | 2002-08-14 | Astrazeneca Ab | New Compounds |
| SE0202465D0 (sv) * | 2002-08-14 | 2002-08-14 | Astrazeneca Ab | New compounds |
| CN1317280C (zh) * | 2003-02-27 | 2007-05-23 | 神经研究公司 | 新的二氮杂双环芳基衍生物 |
| ATE445618T1 (de) * | 2003-02-27 | 2009-10-15 | Neurosearch As | Neue diazabicyclische arylderivate |
| US7399765B2 (en) | 2003-09-19 | 2008-07-15 | Abbott Laboratories | Substituted diazabicycloalkane derivatives |
| US7365193B2 (en) * | 2004-02-04 | 2008-04-29 | Abbott Laboratories | Amino-substituted tricyclic derivatives and methods of use |
| ES2297727T3 (es) * | 2004-06-09 | 2008-05-01 | F. Hoffmann-La Roche Ag | Derivados de octahidropirrolo(3,4-c)pirrol y su empleo como agentes antiviricos. |
| JP5236944B2 (ja) * | 2004-07-22 | 2013-07-17 | カムブァ、アイピー、ヴェンチュァズ、エル、ピー | 微生物感染を治療するためのリファマイシン誘導体 |
| BRPI0611439A2 (pt) * | 2005-05-13 | 2010-09-08 | Lexicon Pharmaceuticals Inc | compostos multicìclicos e métodos para uso dos mesmos |
| TWI454262B (zh) * | 2006-11-02 | 2014-10-01 | Targacept Inc | 菸鹼乙醯膽鹼受體亞型選擇性之二氮雜雙環烷類醯胺 |
-
2007
- 2007-10-19 TW TW101139986A patent/TWI454262B/zh not_active IP Right Cessation
- 2007-10-19 TW TW099135628A patent/TWI404532B/zh not_active IP Right Cessation
- 2007-10-19 TW TW096139391A patent/TWI405763B/zh not_active IP Right Cessation
- 2007-10-30 SA SA07280584A patent/SA07280584B1/ar unknown
- 2007-10-31 PE PE2011000136A patent/PE20110671A1/es not_active Application Discontinuation
- 2007-10-31 PE PE2007001487A patent/PE20081441A1/es not_active Application Discontinuation
- 2007-10-31 CL CL200703155A patent/CL2007003155A1/es unknown
- 2007-11-01 CN CN201210401679.6A patent/CN102942569B/zh not_active Expired - Fee Related
- 2007-11-01 BR BRPI0717930-8A patent/BRPI0717930A2/pt not_active IP Right Cessation
- 2007-11-01 CA CA2663925A patent/CA2663925C/en not_active Expired - Fee Related
- 2007-11-01 DK DK07863786.5T patent/DK2094703T3/da active
- 2007-11-01 JP JP2009535465A patent/JP5539723B2/ja active Active
- 2007-11-01 KR KR1020097008122A patent/KR101415705B1/ko not_active Expired - Fee Related
- 2007-11-01 EP EP07863786A patent/EP2094703B1/en active Active
- 2007-11-01 MY MYPI20091569A patent/MY145602A/en unknown
- 2007-11-01 EP EP10075738A patent/EP2284171B1/en active Active
- 2007-11-01 UA UAA200912807A patent/UA106718C2/uk unknown
- 2007-11-01 PL PL07863786T patent/PL2094703T3/pl unknown
- 2007-11-01 MY MYPI2011004927A patent/MY156730A/en unknown
- 2007-11-01 RU RU2009120674/04A patent/RU2448969C2/ru not_active IP Right Cessation
- 2007-11-01 PT PT07863786T patent/PT2094703E/pt unknown
- 2007-11-01 AU AU2007317433A patent/AU2007317433B2/en not_active Ceased
- 2007-11-01 CN CN2007800402281A patent/CN101528745B/zh not_active Expired - Fee Related
- 2007-11-01 AT AT10075738T patent/ATE545646T1/de active
- 2007-11-01 UY UY30686A patent/UY30686A1/es not_active Application Discontinuation
- 2007-11-01 RU RU2009138600/04A patent/RU2517693C2/ru not_active IP Right Cessation
- 2007-11-01 MX MX2009004801A patent/MX2009004801A/es active IP Right Grant
- 2007-11-01 BR BRPI0722387-0A patent/BRPI0722387A2/pt not_active Application Discontinuation
- 2007-11-01 HR HR20110570T patent/HRP20110570T1/hr unknown
- 2007-11-01 RS RS20110339A patent/RS51834B/sr unknown
- 2007-11-01 CN CN201210291637.1A patent/CN102838605B/zh not_active Expired - Fee Related
- 2007-11-01 KR KR1020107025973A patent/KR20100124356A/ko not_active Abandoned
- 2007-11-01 US US12/447,850 patent/US8114889B2/en not_active Expired - Fee Related
- 2007-11-01 ES ES07863786T patent/ES2395212T3/es active Active
- 2007-11-01 AR ARP070104876A patent/AR063451A1/es not_active Application Discontinuation
- 2007-11-01 AT AT07863786T patent/ATE509022T1/de active
- 2007-11-01 UA UAA200905474A patent/UA98944C2/ru unknown
- 2007-11-01 CN CN2010105367790A patent/CN102020646B/zh not_active Expired - Fee Related
- 2007-11-01 ES ES10075738T patent/ES2395157T3/es active Active
- 2007-11-01 NZ NZ575557A patent/NZ575557A/en not_active IP Right Cessation
- 2007-11-01 SI SI200730628T patent/SI2094703T1/sl unknown
- 2007-11-01 NZ NZ587847A patent/NZ587847A/en not_active IP Right Cessation
- 2007-11-01 WO PCT/US2007/083330 patent/WO2008057938A1/en not_active Ceased
-
2009
- 2009-03-16 IL IL197618A patent/IL197618A/en not_active IP Right Cessation
- 2009-03-26 NO NO20091251A patent/NO20091251L/no not_active Application Discontinuation
- 2009-06-01 CO CO09056352A patent/CO6180435A2/es active IP Right Grant
-
2010
- 2010-03-15 US US12/723,790 patent/US8268860B2/en not_active Expired - Fee Related
- 2010-09-07 AU AU2010219323A patent/AU2010219323B2/en not_active Ceased
- 2010-10-31 IL IL209026A patent/IL209026A/en not_active IP Right Cessation
-
2011
- 2011-01-05 AR ARP110100026A patent/AR079840A2/es not_active Application Discontinuation
- 2011-07-20 CY CY20111100706T patent/CY1112374T1/el unknown
-
2012
- 2012-01-03 US US13/342,635 patent/US8859609B2/en active Active
- 2012-07-23 US US13/555,458 patent/US8921410B2/en active Active
- 2012-11-19 JP JP2012253103A patent/JP5739398B2/ja active Active
-
2014
- 2014-11-24 US US14/551,498 patent/US20150080576A1/en not_active Abandoned
-
2015
- 2015-10-26 US US14/922,473 patent/US9580434B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1112374T1 (el) | Επιλεκτικα του υποτυπου νικοτινικου υποδοχεα της ακετυλχολινης αμιδια διαζαδικυκλοαλκανιων | |
| UA99309C2 (ru) | Замещенные пиперидинодигидротиенопиримидины | |
| NO20050012L (no) | N-aryldiazaspiracykliske forbindelser og fremgangsmater for fremstilling og anvendelse derav | |
| WO2006108965A3 (fr) | Antagonistes npy, preparation et utilisations | |
| ATE455776T1 (de) | Nikotinische alpha-7-rezeptorliganden gegen erkrankungen des zns | |
| DE60231341D1 (de) | Fluor- und sulfonylaminohaltige, 3,6-disubstituierptorantagonisten | |
| WO2006029028A3 (en) | Improved apo e analogs and methods for their use | |
| MY147442A (en) | Imidazoquinolines as lipid kinase inhibitors | |
| DK1362039T3 (da) | Heterocykliske, substituerede carbonylderivater og deres anvendelse som dopamin D3-receptorligander | |
| WO2008020306A3 (en) | Isoindole derivatives | |
| MX2009014001A (es) | Derivados de isoxazol-imidazol. | |
| MX2009010630A (es) | Derivados de azabicicloalcano selectivos de sub-tipo. | |
| WO2002081745A3 (en) | Genes involved in osteogenesis, and methods of use | |
| WO2007100430A3 (en) | Cytisine and acetylcholine analogs and methods of treating mood disorders | |
| UY30959A1 (es) | Subtipo de amidas selectivas de diazabicicloalcanos | |
| WO2007058805A3 (en) | Compositions and methods for treating cns disorders | |
| WO2006029142A3 (en) | Methods and systems for treating asthma and other respiratory diseases | |
| WO2007106862A3 (en) | The use of statins to stimulate neurogenesis | |
| ATE495271T1 (de) | Zusammensetzungen und verfahren zum nachweis von störungen in verbindung mit histamin | |
| EA200701856A1 (ru) | Тетрагидропиридоазепин-8-оны и родственные соединения для лечения шизофрении | |
| ATE407126T1 (de) | Herstellung von (s)-4-fluormethyl-dihydro-furan-2-on | |
| CL2008003232A1 (es) | Compuestos derivados de bencensulfonanilida; composición farmacéutica que los comprende; y uso en el tratamiento de enfermedades del sistema nervioso central, disfunciones cognitivas, esquizofrenia, enfermedades adictivas, enfermedad de alzheimer u obesidad. | |
| WO2006018708A3 (en) | Pyrrolidine derivatives as muscarinic receptor antagonists | |
| DE602006017849D1 (de) | 5,6-disubstituierte oxadiazolopyrazine und thiadiazolopyrazine als liganden des cxc-chemokinrezeptors | |
| ECSP099377A (es) | Amidas de diazabicicloalcanos selectivas del subtipo del receptor nicotínico de acetilcolina |